Drugs / Meningococcal Vaccine
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT03562377 | Jul 2018 → Sep 2019 | atopic eczema | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01210885 | Dec 2010 → Jul 2011 | meningococcal meningitis | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00126945 | Aug → Oct 2005 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00239694 | Apr 2001 → Aug 2012 | — | National Institute on Aging (NIA) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04704830 Background | Apr 2021 → Mar 2023 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-28 | Pfizer | U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents pfizer.com ↗ |
| 2022-09-15 | Pfizer | Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents pfizer.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00126945 ↗ |
| Known as | MenABCWY | “MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.” NCT01210885 ↗ |
| Modality | Vaccine | “Meningococcal Conjugate Vaccine” NCT00126945 ↗ |
| Route | Intramuscular | “intramuscular (IM) administration” NCT01210885 ↗ |